Summary.
Deprenyl, an irreversible MAO-B inhibitor, is known to have a symptomatic effect in de novo patients with Parkinson's disease (PD). It has, however, not been studied thoroughly in patients with advanced PD and response fluctuations. This study evaluated the effect of washout of deprenyl in patients with long-standing PD. Eleven PD patients who were on chronic treatment with deprenyl (mean age 57 ± 8 years, mean disease duration 8.4 ± 2.9 years), seven with response fluctuations, were enrolled in a double-blind study of a novel MAO-B inhibitor. A deprenyl washout period of one month was required prior to initiation of treatment with the trial drug. Patients were evaluated by Unified Parkinson's Disease Rating scale (UPDRS) before and one month after the washout period. Motor function was quantified by computerized tapping speed and movement time test. Results showed that neither total UPDRS scores (22 ± 16 vs. 18 ± 16, respectively) nor tapping speed and movement time changed significantly (4.4 ± 0.5 vs. 4.2 ± 0.3 Hz and 159 ± 45 vs. 161 ± 40 seconds; p > 0.1, respectively). However, eight patients reported various degrees of subjective deterioration, among them were the seven fluctuating patients. Two patients first began to experience response fluctuations during the washout period. It seems that deprenyl has a symptomatic effect, especially in patients with response fluctuations, and it may postpone the appearance of fluctuations in patients with PD. Attempts to discontinue treatment with deprenyl may aggravate disease symptoms.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received October 26, 2001; accepted January 30, 2002
Rights and permissions
About this article
Cite this article
Djaldetti, R., Ziv, I. & Melamed, E. The effect of deprenyl washout in patients with long-standing Parkinson's disease. J Neural Transm 109, 797–803 (2002). https://doi.org/10.1007/s007020200066
Issue Date:
DOI: https://doi.org/10.1007/s007020200066